Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen-activated protein kin...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Juratli, Tareq A., Jones, Pamela S., Wang, Nancy, Subramanian, Megha, Aylwin, Simon J.B., Odia, Yazmin, Rostami, Elham, Gudjonsson, Olafur, Shaw, Brian L., Cahill, Daniel P., Galanis, Evanthia, Barker, Fred G., Santagata, Sandro, Brastianos, Priscilla K.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7032527/
https://ncbi.nlm.nih.gov/pubmed/31314136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32197
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items